User profiles for Victoria J. Cook
 | Victoria CookUniversity of British Columbia Verified email at bccdc.ca Cited by 5017 |
[HTML][HTML] Whole-genome sequencing and social-network analysis of a tuberculosis outbreak
Background An outbreak of tuberculosis occurred over a 3-year period in a medium-size
community in British Columbia, Canada. The results of mycobacterial interspersed repetitive unit…
community in British Columbia, Canada. The results of mycobacterial interspersed repetitive unit…
[HTML][HTML] Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
Background A 9-month regimen of isoniazid can prevent active tuberculosis in persons with
latent tuberculosis infection. However, the regimen has been associated with poor …
latent tuberculosis infection. However, the regimen has been associated with poor …
[HTML][HTML] Tuberculosis and chronic kidney disease: an emerging global syndemic
The link between chronic kidney disease (CKD) and tuberculosis (TB) has been known for
more than 40 years, but the interaction between these 2 diseases is still poorly understood. …
more than 40 years, but the interaction between these 2 diseases is still poorly understood. …
[HTML][HTML] Treatment outcomes from community-based drug resistant tuberculosis treatment programs: a systematic review and meta-analysis
Background There is increasing evidence that community-based treatment of drug resistant
tuberculosis (DRTB) is a feasible and cost-effective alternative to centralized, hospital-based …
tuberculosis (DRTB) is a feasible and cost-effective alternative to centralized, hospital-based …
Transmission network analysis in tuberculosis contact investigations
Background. Social network analysis (SNA) is an innovative approach to the collection and
analysis of infectious disease transmission data. We studied whether this approach can …
analysis of infectious disease transmission data. We studied whether this approach can …
Conventional methods versus 16S ribosomal DNA sequencing for identification of nontuberculous mycobacteria: cost analysis
VJ Cook, CY Turenne, J Wolfe, R Pauls… - Journal of clinical …, 2003 - Am Soc Microbiol
The clinical profile of nontuberculous mycobacteria (NTM) has been raised by the human
immunodeficiency virus and AIDS pandemic. Different laboratory techniques, often molecular …
immunodeficiency virus and AIDS pandemic. Different laboratory techniques, often molecular …
Longitudinal Clinical Findings and Outcome Among Patients With Cryptococcus gattii Infection in British Columbia
Background. Cryptococcus gattii (Cg) infection emerged in British Columbia in 1999. A
longitudinal, clinical description of patients has not been reported. Methods. Medical records …
longitudinal, clinical description of patients has not been reported. Methods. Medical records …
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials
Background An important problem limiting treatment of latent tuberculosis infection is the
occurrence of adverse events with isoniazid. We combined populations from phase 2 and …
occurrence of adverse events with isoniazid. We combined populations from phase 2 and …
Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population
…, J Halaschek-Wiener, M Chan, VJ Cook… - …, 2009 - Future Medicine
… Victoria J Cook is supported in part by in it for life, Vancouver Coastal Health Research
Institute. J Mark Fitzgerald is a recipient of a Michel Smith Distinguished Scholar Award and a …
Institute. J Mark Fitzgerald is a recipient of a Michel Smith Distinguished Scholar Award and a …
[HTML][HTML] Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial
…, H Alsdurf, S Anagonou, VJ Cook… - The Lancet Public …, 2021 - thelancet.com
Background Reaching the UN General Assembly High-Level Meeting on Tuberculosis
target of providing tuberculosis preventive treatment to at least 30 million people by 2022, …
target of providing tuberculosis preventive treatment to at least 30 million people by 2022, …